Haematologica

Haematologica www.haematologica.org publishes novel findings in basic, clinical and translational hematology research. Impact Factor (JCR) 7.116 (7th of 76)

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recom

mendations on publication ethics policies for medical journals. Haematologica was founded in 1920 by Adolfo Ferrata

Can bleomycin be safely omitted from the treatment of limited-stage Hodgkin lymphoma?For patients with limited-stage cla...
20/08/2026

Can bleomycin be safely omitted from the treatment of limited-stage Hodgkin lymphoma?
For patients with limited-stage classical Hodgkin lymphoma and a negative positron emission tomography (PET) scan after two cycles of ABVD, reducing treatment toxicity without compromising cure remains a key goal.
Yang et al. evaluate a PET-adapted approach that omits bleomycin after cycle 2, exploring its impact on clinical outcomes and treatment-related pulmonary toxicity.
Read more in Haematologica.
https://haematologica.org/article/view/13373

What does lymphocytosis after BCMA chimeric antigen receptor (CAR) T-cell therapy really represent?Transient lymphocytos...
18/08/2026

What does lymphocytosis after BCMA chimeric antigen receptor (CAR) T-cell therapy really represent?
Transient lymphocytosis is commonly observed after BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma, but its interpretation can be challenging in routine practice.
Chai et al. characterize the morphological and immunophenotypic features of post-infusion lymphocytosis and explore how CAR T-cell expansion kinetics may relate to treatment response and neurotoxicity.
Read the full Letter in Haematologica.
https://haematologica.org/article/view/13127

Evidence supporting CD19-directed chimeric antigen receptor (CAR) T-cell therapy in intravascular large B-cell lymphoma ...
16/08/2026

Evidence supporting CD19-directed chimeric antigen receptor (CAR) T-cell therapy in intravascular large B-cell lymphoma (IVLBCL) remains extremely limited, leaving important questions about its efficacy and safety unanswered.
Using real-world data from the CIBMTR registry, Patel et al. explore the outcomes of patients with relapsed or refractory IVLBCL treated with CAR T cells, providing new insights into this rare and challenging disease.
Read the full Letter in Haematologica.
https://haematologica.org/article/view/12984

How often do patients with T-follicular helper cell lymphoma develop a subsequent myeloid neoplasm?Clonal hematopoiesis ...
14/08/2026

How often do patients with T-follicular helper cell lymphoma develop a subsequent myeloid neoplasm?
Clonal hematopoiesis is a hallmark of T-follicular helper cell lymphomas, but its clinical consequences are still being defined.
Lin et al. investigate the incidence of subsequent myeloid neoplasms and explore the clinical and molecular factors that may contribute to their development.
Read the full Letter in Haematologica.
https://haematologica.org/article/view/13023

Is mantle cell lymphoma relapse already written at diagnosis?Why do some patients experience long-lasting remissions whi...
12/08/2026

Is mantle cell lymphoma relapse already written at diagnosis?
Why do some patients experience long-lasting remissions while others relapse despite frontline chemoimmunotherapy?
By comparing the genomic landscape of mantle cell lymphoma at diagnosis and relapse, a new study sheds light on the origins of disease progression and offers important insights into the biology of treatment resistance.
Read more in Haematologica.
https://haematologica.org/article/view/13012

Could a simple blood test improve the diagnosis and monitoring of pediatric immune cytopenias?Distinguishing Evans syndr...
10/08/2026

Could a simple blood test improve the diagnosis and monitoring of pediatric immune cytopenias?
Distinguishing Evans syndrome from other immune cytopenias can be challenging, and reliable biomarkers are still lacking.
Harris et al. investigate the clinical value of circulating T follicular helper cells, exploring whether they can identify distinct disease phenotypes, reflect disease activity, and reveal underlying immune dysregulation.
Read more in Haematologica.
https://haematologica.org/article/view/12941

Why do some acute myeloid leukemia cells escape BCL2 inhibition?Venetoclax has transformed the treatment landscape of ac...
08/08/2026

Why do some acute myeloid leukemia cells escape BCL2 inhibition?
Venetoclax has transformed the treatment landscape of acute myeloid leukemia (AML), yet resistance remains a major obstacle.
In this issue of Haematologica, Brim-Edwards et al. address this clinical and biological problem by identifying novel shared mediators of resistance to both venetoclax and the dual BCL2/BCL2L1 inhibitor AZD4320, thereby extending our understanding of apoptotic plasticity and its regulation in AML.
Could differentiation state hold the key to overcoming treatment resistance?
Read the study to discover how these pathways may help inform future therapeutic strategies.
https://haematologica.org/article/view/12940

What happens when two distinct B-cell clones coexist in the same patient?Concurrent λ AL amyloidosis (or light chain dep...
06/08/2026

What happens when two distinct B-cell clones coexist in the same patient?
Concurrent λ AL amyloidosis (or light chain deposition disease) and a κ-restricted B-cell lymphoproliferative disorder are exceptionally rare, creating unique diagnostic and therapeutic challenges.
In this Case Series, Cetin et al. describe six patients with this unusual dual-clone phenomenon and discuss its implications for diagnosis, treatment selection, and response assessment.
Read the full Case Series in Haematologica.
https://haematologica.org/article/view/13460

Landmark Paper in Hematology: How can the host response enhance leukemia treatment?The pioneering work of Karp and Burke...
06/08/2026

Landmark Paper in Hematology: How can the host response enhance leukemia treatment?
The pioneering work of Karp and Burke showed that humoral factors induced after chemotherapy can increase the sensitivity of residual leukemic blasts to subsequent cytotoxic treatment.
Their findings laid the foundation for the development of treatment strategies incorporating growth factors such as G-CSF, ultimately contributing to regimens such as FLAG and influencing today's approaches combining G-CSF with novel therapies, including azacitidine and venetoclax.
This landmark discovery highlights how understanding the host's biological response to treatment has helped optimize antileukemic therapy and continues to inform therapeutic innovation in acute myeloid leukemia.
Read more in Haematologica.
https://haematologica.org/article/view/14298

Indirizzo

Via Giuseppe Belli 4
Pavia
27100

Orario di apertura

Lunedì 09:00 - 18:00
Martedì 09:00 - 18:00
Mercoledì 09:00 - 18:00
Giovedì 09:00 - 18:00
Venerdì 09:00 - 18:00

Telefono

+39038227129

Sito Web

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Haematologica pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta La Scuola/università

Invia un messaggio a Haematologica:

Scelte rapide

Condividi